...an ODC polymorphism and excretion of 4 urinary polyamines. The Tillotts Pharma AG subsidiary of Zeria... ...North America (see BioCentury, Feb. 1, 2016 ). Cancer Prevention Pharmaceuticals Inc. , Tucson, Ariz. Zeria... ...of 4 urinary polyamines Status: Phase III ongoing Milestone: NA
Meghan Sullivan
CPP-1X/sulindac
DFMO/sulindac
eflornithine/sulindac
Cancer Prevention Pharmaceuticals Inc.
Sucampo Pharmaceuticals Inc.
Zeria...
...has U.S. rights to the non-dextran IV iron replacement from Galenica Ltd. (SIX:VIFN). Galenica granted Zeria... ...treat iron deficiency anemia (see BioCentury, Aug. 19, 2013 ). Galenica Ltd. (SIX:VIFN), Bern, Switzerland Zeria... ...6-minute walk test (6MWT) Status: Phase III started Milestone: NA
Alicia Parker
Ferinject
ferric carboxymaltose
Injectafer
Z-213
Daiichi Sankyo Co. Ltd.
Galenica Ltd.
Zeria...
...once daily vs. each of its components -- eflornithine or sulindac -- for 2 years. Zeria’s... ...product in North America (see BioCentury, Feb. 1). Cancer Prevention Pharmaceuticals Inc. , Tucson, Ariz. Zeria...
...Numab granted Zeria’s Tillotts Pharma AG unit exclusive, worldwide rights to develop and commercialize antibodies against... ...to double digits. The companies declined to disclose financial details. Numab AG , Waedensil, Switzerland Zeria...
...Eisai granted Zeria exclusive rights to develop and co-promote E3710 in Japan. Eisai will receive an... ...develop and co-promote E3710 in Japan. Eisai will receive an undisclosed upfront payment, plus royalties. Zeria... ...diseases. The partners could not be reached for details. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Zeria...
...least 53 countries and is known as Ferinject outside North America. Last August, Galenica granted Zeria... ...Aug. 19, 2013). Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Galenica Ltd. (SIX:GALN), Bern, Switzerland Zeria...
